Table 2 Patient and tumor characteristics in the neoadjuvant and adjuvant groups from the studies
First author | N NACT/ACT | Median age (year) | Clinical stage | Nuclear grade | Histology | Local treatment | ||||
|---|---|---|---|---|---|---|---|---|---|---|
NACT/ACT | NACT | ACT | NACT | ACT | NACT | ACT | ||||
I/II/III | I/II/III | 1/2/3 | 1/2/3 | IDC/ILC/Other | IDC/ILC/Other | M | B | |||
Clifton | 132/187 | < 50, 102/144 | 15/70/0 | 20/65/0 | 0/4/81 | 2/1/79 | 84/0/1 | 83/0/2 | 162 | 157 |
≥ 50, 30/43 | ||||||||||
Fisher | 151/234 | < 50, 82/96 | 10/85/49 | 81/91/11 | 2/15/130 | 2/25/200 | 120/7/24 | 190/7/37 | NR | NR |
≥ 50, 69/138 | ||||||||||
Kennedy | 154/251 | 50/53 | 3/80/43 | 89/101/19 | 0/14/135 | 5/34/197 | 130/14/10 | 198/28/25 | 207 | 198 |
Sharma | 67/79 | 52/58 | NR | NR | NR | NR | NR | NR | NR | NR |
Cheng | 4335/11,148 | < 50, 1951/3456 | NR/NR/1517 | NR/NR/669 | NA | NA | NR | NR | NR | NR |
≥ 50, 2384/7692 | ||||||||||
Yang | 36/31 | NA | NA | NA | NR | NR | NA | NA | NR | NR |
Biswas | 202/218 | 51/51 | 1/105/96 | 69/117/32 | NA | NA | NR | NR | NA | NA |
Bagegni | 5621/13,530 | 51.9/55.7 | 0/3843/1778 | 0/12142/13,88 | 26/649/4530 | 102/1328/11,391 | NR | NR | NR | NR |
Philipovskiy | 30/74 | 50.4/53 | 3/11/16 | 16/41/17 | NR | NR | 100/0/4a | 45 | 54 | |